2024-09-24 04:44:57
This is an unprecedented conviction in a context of drug shortages. The health authorities have just ordered around ten pharmaceutical laboratories to pay a total of 8 million euros for not having maintained sufficient stocks of treatments deemed essential, they announced on Tuesday September 24.
“The National Medicines Safety Agency (ANSM) imposes 8 million euros in financial sanctions against pharmaceutical laboratories which have not respected their four months of safety stock”she said in a press release.
Read also | Article reserved for our subscribers Shortages of medicines: the National Assembly establishes a minimum stock obligation
Add to your selections
The law has been tightened in recent years towards pharmaceutical groups in order to strengthen their obligations in terms of drug stocks. These measures, taken as drug shortages worsen from year to year, force companies to maintain stocks of two months, or in some cases four months, of drugs said to be of major therapeutic interest. These medications are those for which an interruption of treatment can endanger the patient’s life in the short or medium term.
The sanctions announced on Tuesday, which correspond to breaches observed in 2023, are unprecedented. For 2022, barely more than 500,000 euros in sanctions had been imposed.
Biogaran, Sandoz or Viatris sanctioned
This time, around thirty references are concerned and cover a broad therapeutic spectrum. “The shortcomings identified concern, for example, anti-hypertensive drugs, anti-cancer drugs, antimicrobials, neurology drugs…”Alexandre de La Volpilière, director general of the ANSM, explained to Agence France-Presse. “Unfortunately, no class is spared from this phenomenon. »
“In the laboratories, the main ones are Biogaran, Sandoz, Viatris: the biggest sanctions concern generic drugs, which corresponds to the main supply disruptions that we have seen in recent years”he added.
Read also | Article reserved for our subscribers Shortages of pediatric amoxicillin: the government refines its winter plan
Add to your selections
One of the biggest sanctions affects, for example, Biogaran, a large French group specializing in generics, for insufficient stocks of a molecule against hypertension, irbesartan.
These announcements were favorably received by patient associations, concerned about worsening treatment shortages. “It’s a good signal, since before the fines were much lower”welcomes Catherine Simonin, from France Assos Santé, which brings together numerous associations. She sees it as a sign that “checks are done”.
Reuse this content
1727439880
#context #drug #shortages #France #ten #laboratories #ordered #pay #million #euros #stocked
